Kanamycin

Class: Aminoglycoside

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-positive (incl. Mycobacterium tuberculosis) and Gram-negative bacteria
Description:	Streptomyces natural compound, closely related to amikacin. Veterinary use, human use in tuberculosis and topical formulations
Year first mentioned:	1957
Highest developmental phase:	Approved by FDA in 1973
Development status:	Discontinued

Chemical structure(s):
Canonical SMILES:	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@@H](CN)O2)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)N)O)N
Isomeric SMILES:	C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N
InChI:	InChI=1S/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1
InChI Key:	SBUJHOSQTJFQJX-NOAMYHISSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/6032

External links:
Guide to Pharmacology:	kanamycin
Main Source:	https://pubmed.ncbi.nlm.nih.gov/5294626/
Citations:	https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/563437 https://pubmed.ncbi.nlm.nih.gov/5294626/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661289/